Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Roszet. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Ezetimibe; Rosuvastatin Calcium (sold as Roszet), first approved Mar 23, 2021, with 1 new use approved and 1 published complete response letter.
Rosuzet, new approvalNew combination drugs indicated for the treatment of hypercholesterolemia and familial hypercholesterolemia. · MSD K.K. · Mar 26, 2019 · Review report
Clinical Trials
33 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Rosuvastatin and ezetimibeProduct Quality, Facility Inspections, Information Needed To Resolve Deficiencies
Approved
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
